{"id":62900,"date":"2026-04-12T11:35:33","date_gmt":"2026-04-12T03:35:33","guid":{"rendered":"https:\/\/flcube.com\/?p=62900"},"modified":"2026-04-12T11:35:34","modified_gmt":"2026-04-12T03:35:34","slug":"konruns-pharma-wins-nmpa-approval-for-kc1036-phase-iii-in-esophageal-cancer-multi-target-tki-advances-in-2l-escc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62900","title":{"rendered":"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC"},"content":{"rendered":"\n<p><strong>Konruns Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603590:SHA\">SHA:\u202f603590<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved initiation of a <strong>Phase III clinical study<\/strong> for <strong>KC1036<\/strong>, a <strong>multi\u2011target tyrosine kinase inhibitor (TKI)<\/strong>, in <strong>advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC)<\/strong>. The trial will evaluate KC1036 in patients who have <strong>progressed after first\u2011line therapy<\/strong> with <strong>immune checkpoint inhibitors plus chemotherapy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Phase III clinical trial authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>KC1036 (Category\u202f1 chemical drug)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced recurrent\/metastatic ESCC (2L+)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Failed prior PD\u20111\/PD\u2011L1 + chemotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target<\/th><th>Function<\/th><th>Therapeutic Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>VEGFR2<\/strong><\/td><td>Vascular endothelial growth factor receptor 2<\/td><td><strong>Anti\u2011angiogenesis<\/strong> \u2013 inhibits tumor blood vessel formation and nutrient supply<\/td><\/tr><tr><td><strong>AXL<\/strong><\/td><td>Receptor tyrosine kinase<\/td><td><strong>Immune modulation<\/strong> \u2013 enhances host anti\u2011tumor immune response, prevents tumor immune evasion<\/td><\/tr><tr><td><strong>FLT3<\/strong><\/td><td>Fms\u2011like tyrosine kinase 3<\/td><td>Tumor cell proliferation inhibition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Multi\u2011kinase inhibition simultaneously blocks <strong>angiogenic signaling<\/strong> (VEGFR2) and <strong>immune escape pathways<\/strong> (AXL), offering <strong>synergistic anti\u2011tumor activity<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Dual angiogenesis + immune\u2011enhancement mechanism distinct from single\u2011target VEGFR inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-strategy\">Clinical Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase III Design:<\/strong> Randomized controlled trial comparing KC1036 vs. standard of care in 2L+ ESCC<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> ESCC represents <strong>>90% of esophageal cancers in China<\/strong>; 2L treatment options limited after immunotherapy progression<\/li>\n\n\n\n<li><strong>Market Context:<\/strong> China accounts for <strong>~50% of global ESCC cases<\/strong>; incidence concentrated in northern regions with heavy tobacco\/alcohol exposure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Esophageal Cancer Landscape:<\/strong> Global market <strong>US$2\u20113\u202fbillion<\/strong>; China represents largest addressable population with <strong>~300,000 annual new cases<\/strong><\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong><\/li>\n\n\n\n<li><strong>First\u2011line:<\/strong> Dominated by PD\u20111\/PD\u2011L1 + chemo (Camrelizumab, Sintilimab, etc.)<\/li>\n\n\n\n<li><strong>Second\u2011line:<\/strong> Limited approved options; KC1036 targets <strong>post\u2011IO failure population<\/strong> with novel mechanism<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Peak China sales projected at <strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (US$110\u2011165\u202fmillion) by 2030 assuming 15\u201120% 2L market share<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Multi\u2011target TKI platform applicable to <strong>gastric cancer, hepatocellular carcinoma<\/strong>, and other VEGFR\u2011driven tumors<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial outcomes, regulatory pathways, and commercial projections for KC1036. Actual results may differ due to risks including efficacy failures, safety signals, competitive entry, and reimbursement negotiations in China&#8217;s oncology market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603590_20260410_7EPP.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603590_20260410_7EPP.\"><\/object><a id=\"wp-block-file--media-6bb21bfc-b72d-4605-a633-cc86c2e07f88\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603590_20260410_7EPP.pdf\">603590_20260410_7EPP<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/603590_20260410_7EPP.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6bb21bfc-b72d-4605-a633-cc86c2e07f88\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China&#8217;s National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,2984,1532],"class_list":["post-62900","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-konruns-pharmaceutical","tag-sha-603590"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China&#039;s National Medical Products Administration (NMPA) has approved initiation of a Phase III clinical study for KC1036, a multi\u2011target tyrosine kinase inhibitor (TKI), in advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The trial will evaluate KC1036 in patients who have progressed after first\u2011line therapy with immune checkpoint inhibitors plus chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62900\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC\" \/>\n<meta property=\"og:description\" content=\"Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China&#039;s National Medical Products Administration (NMPA) has approved initiation of a Phase III clinical study for KC1036, a multi\u2011target tyrosine kinase inhibitor (TKI), in advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The trial will evaluate KC1036 in patients who have progressed after first\u2011line therapy with immune checkpoint inhibitors plus chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62900\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-12T03:35:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-12T03:35:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62900#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62900\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC\",\"datePublished\":\"2026-04-12T03:35:33+00:00\",\"dateModified\":\"2026-04-12T03:35:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62900\"},\"wordCount\":376,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Konruns Pharmaceutical\",\"SHA: 603590\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62900#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62900\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62900\",\"name\":\"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-12T03:35:33+00:00\",\"dateModified\":\"2026-04-12T03:35:34+00:00\",\"description\":\"Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved initiation of a Phase III clinical study for KC1036, a multi\u2011target tyrosine kinase inhibitor (TKI), in advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The trial will evaluate KC1036 in patients who have progressed after first\u2011line therapy with immune checkpoint inhibitors plus chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62900#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62900\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62900#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC - Insight, China&#039;s Pharmaceutical Industry","description":"Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved initiation of a Phase III clinical study for KC1036, a multi\u2011target tyrosine kinase inhibitor (TKI), in advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The trial will evaluate KC1036 in patients who have progressed after first\u2011line therapy with immune checkpoint inhibitors plus chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62900","og_locale":"en_US","og_type":"article","og_title":"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC","og_description":"Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved initiation of a Phase III clinical study for KC1036, a multi\u2011target tyrosine kinase inhibitor (TKI), in advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The trial will evaluate KC1036 in patients who have progressed after first\u2011line therapy with immune checkpoint inhibitors plus chemotherapy.","og_url":"https:\/\/flcube.com\/?p=62900","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-12T03:35:33+00:00","article_modified_time":"2026-04-12T03:35:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62900#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62900"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC","datePublished":"2026-04-12T03:35:33+00:00","dateModified":"2026-04-12T03:35:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62900"},"wordCount":376,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial approval \/ initiation","Konruns Pharmaceutical","SHA: 603590"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62900#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62900","url":"https:\/\/flcube.com\/?p=62900","name":"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-12T03:35:33+00:00","dateModified":"2026-04-12T03:35:34+00:00","description":"Konruns Pharmaceutical Co., Ltd (SHA:\u202f603590) announced that China's National Medical Products Administration (NMPA) has approved initiation of a Phase III clinical study for KC1036, a multi\u2011target tyrosine kinase inhibitor (TKI), in advanced recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The trial will evaluate KC1036 in patients who have progressed after first\u2011line therapy with immune checkpoint inhibitors plus chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62900#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62900"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62900#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer \u2013 Multi\u2011Target TKI Advances in 2L+ ESCC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62900"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62900\/revisions"}],"predecessor-version":[{"id":62902,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62900\/revisions\/62902"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}